Pricing Log in Create free account
Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue
+27.0%
EPS
−40.3%
Free cash flow
−140.2%
Total debt
+4.46%

Quarter to September 2026, against a year earlier

25.15 0.88 −3.38%
Market cap
$7.4B
P/E
77.7×
Fwd P/E
254×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Caris Life Sciences,�Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:01 PM ET · Document on sec.gov · Filing index

Red flags

  • Material weakness

    Caris Life Sciences,�Inc.’s 10-Q reports a material weakness in internal control over financial reporting

    Other than the foregoing actions to remediate our material weakness, there was no change in our internal control over financial reporting identified during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

    10-Q filed · The filing · sec.gov

  • Receivables outpacing revenue

    Receivables grew 399.4% while revenue grew 27.0% year over year

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 1 added · 19 removed · 38 modified; 14 with only figures updated

  1. Modified · Overview

    We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 18 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on tests we have run on over 1,130,0001,200,000 cases as of JuneSeptember 30, 2026. Our Caris Molecular Intelligence platform is purpose-built to leverage the convergence of next-generation sequencing (“NGS”), AI and ML technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including multi-cancer early detection (“MCED”), early detection, minimal residual disease (“MRD”) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics.